Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
Status:
Terminated
Trial end date:
2015-10-27
Target enrollment:
Participant gender:
Summary
This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of
investigational drugs that can be safely tolerated and to define the side effects that limit
the dose. The drug administered in this study is KML-001. It is a highly soluble, orally
available arsenic agent. It is currently being tested to determine its effects on telomerase
activity.
In other words, the purpose of this research study is to find the highest dose of KML001,
that can be given without causing severe side effects when it is combined with a standard,
commercially available anti-cancer drug called cisplatin.
Phase:
Phase 1
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore